Lantern Pharma Inc. (LTRN) stock
Close on Nov 11, 2026Market cap $6.15MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $6.15M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$18.65M
- EPS, diluted
- -$1.62
- Free cash flow
- -$15.68M
- Book value per share
- -$0.26
- Diluted shares
- 12M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $0.46
- Open
- $0.51
- Day's range
- $0.47 – $0.51
- Volume
- 157,203
- Average volume (20 days)
- 278,358
- Beta (5 years)
- 1.63
- 52-week range
- $0.45 – $4.34
- RSI (14 days)
- 28.9
- Volatility (1 year)
- 105.4%
- Relative volume
- 0.75×
- WACC
- 13.0%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | LTRN | S&P 500 | Difference | LTRN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -40.8% | -2.4% | −38.4 pts | ||
| 3 months | -82.7% | -1.2% | −81.5 pts | ||
| Year to date | -84.1% | +12.3% | −96.4 pts | ||
| 1 year | -86.4% | +12.4% | −98.9 pts | ||
| 3 years | -85.4% | +78.8% | −164.2 pts | -47.4% | +21.4% |
| 5 years | -95.0% | +75.2% | −170.2 pts | -45.2% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lantern Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Update
- Update
About Lantern Pharma
Pharmaceutical Preparations
Lantern Pharma Inc. is an artificial intelligence-focused biotechnology company dedicated to developing targeted cancer therapies. The company operates a proprietary machine learning and big data analytics platform called RADR to identify biologically relevant genomic signatures, discover drug candidates, and match therapies with specific cancer patient populations likely to respond. Its clinical-stage portfolio focuses on small molecule oncology candidates, including lead programs LP-300, LP-184, and LP-284, addressing solid tumors and blood cancers. Additionally, the company advances an antibody-drug conjugate development program, an AI platform named withZeta.ai for rare cancer research, and central nervous system oncology candidates through its subsidiary, Starlight Therapeutics.
Company profile, executives and historyLantern Pharma stock: common questions
What is Lantern Pharma's stock price?
LTRN closed at $0.48 on Nov 11, 2026, up 3.89% on the day. Over the past 52 weeks it traded between $0.45 and $4.34.
What is Lantern Pharma's market cap?
Lantern Pharma was worth $6.15M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is LTRN's P/E ratio?
Lantern Pharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.62), so it has no meaningful P/E ratio.
Does Lantern Pharma pay a dividend?
No. Lantern Pharma has not paid a cash dividend over the last twelve months.
When does Lantern Pharma report earnings next?
Lantern Pharma is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has LTRN stock performed over the past year?
Including dividends, LTRN returned -86.4% over the past year, against +12.4% for the S&P 500.
How many LTRN shares are sold short?
1M shares were sold short at the latest FINRA report, 9.07% of the float, or 2.7 days of average trading volume.
Who are Lantern Pharma's competitors?
Companies most similar to Lantern Pharma by business, industry and size include LNAI, PRLD, ALLR, CLRB, FHTX.
See a number that looks wrong?